---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-349490"
form_type: "8-K"
ticker: "MPLT"
cik: "0001770069"
company_name: "MapLight Therapeutics, Inc."
filed_at: "2026-08-13T20:51:37+00:00"
generated_at: "2026-08-13T20:53:11.290877+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MapLight raises $150M PIPE, Q2 net loss $60.2M; ZEPHYR Phase 2 met primary endpoint

## Summary
- $150M PIPE: 9,197,887 shares at $11.38/share plus pre-funded warrants for 3,983,168 shares; closes Aug 14, 2026
- Q2 2026 net loss $60.2M vs $29.8M YoY; R&D $53.4M vs $26.8M; cash $351.3M at June 30, 2026
- Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia met primary endpoint; Phase 3 ZEPHYR-2 topline expected 2028
- Phase 2 VISTA trial in Alzheimer's disease psychosis enrolling; topline expected H2 2027; Fast Track designation
- ML-004 Phase 2 IRIS missed primary endpoint in autism; showed improvement in adolescent irritability subgroup

## SEC filing metadata
- accession: 0001193125-26-349490
- form_type: 8-K
- ticker: MPLT
- cik: 0001770069
- company_name: MapLight Therapeutics, Inc.
- filed_at: 2026-08-13T20:51:37+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770069/000119312526349490/0001193125-26-349490-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770069/000119312526349490/d48818d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-349490
- JSON: https://secwatch.observer/filing/0001193125-26-349490.json
- Plain text: https://secwatch.observer/filing/0001193125-26-349490.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.